Using biomarkers may allow for detection of Alzheimer’s disease at its earliest stages, perhaps even before symptoms are evident. These biomarkers may also be used to evaluate disease progression. Early detection may allow for treatment before any irreparable damage has occurred.
There are a number of biomarkers considered to be important to the assessment of Alzheimer’s disease. These include:
- APOE Gene
- Abeta and Tau proteins
- Amyloid Precursor Protein (APP)
Biomarkers with clinically established normal and pathological ranges would be vital for demonstrating efficacy in clinical studies.